DCM
TBPH icon

Driehaus Capital Management’s Theravance Biopharma TBPH Stock Holding History

Driehaus Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-32,666
Closed -$1.3M – 595
2017
Q2 		$1.3M Sell
32,666
-867
-3% -$33.3K 0.05% 311
2017
Q1 		$1.24M Buy
+33,533
New +$1.07M 0.04% 334

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Driehaus Capital Management's TBPH Position: Q3 2017 in Review

Driehaus Capital Management sold out of Theravance Biopharma (TBPH) in Q3 2017, closing a stake of 32,666 shares — an estimated $1.3M sold.

Driehaus Capital Management first reported a position in TBPH in Q1 2017 and held it in 2 quarters. The position peaked at $1.3M in Q2 2017. 84 funds tracked by Wall St. Rank hold TBPH as of Q3 2017.

  • Driehaus Capital Management reported no remaining Theravance Biopharma position as of Q3 2017 after selling out during the quarter.
  • Driehaus Capital Management sold 32,666 Theravance Biopharma shares in Q3 2017, an estimated $1.3M.
  • Driehaus Capital Management first reported a position in Theravance Biopharma in Q1 2017 and held it in 2 quarters.
  • Driehaus Capital Management's Theravance Biopharma position peaked at $1.3M in Q2 2017.
  • 84 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2017.

Based on Driehaus Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.